

Medsafe Clozapine Survey 2023: Survey questions for pharmacists		
Question	Answer	
Page 1: Your details		
What is your name?	Please answer below	
What is your email address (or other contact details)?	Please answer below	
What is your ethnicity?	Please answer below	
Please select from below which best describes you.	<ul> <li>Individual who takes clozapine</li> <li>Whānau, family and/or caregiver of an individual who takes clozapine</li> <li>Medical doctor</li> <li>Pharmacist</li> <li>Nurse</li> <li>Other healthcare professional</li> </ul>	
We intend to publish the submissions from this survey, but we will only publish your submission if you give permission. We will remove personal details such as email addresses and the names of individuals, and any other information that you tell us to remove. If you do not want your submission published, please let us know below.	<ul> <li>You may publish this submission.</li> <li>Do not publish this submission.</li> </ul>	
Official Information Act responses: Your submission will be subject to requests made under the Official Information Act (even if it hasn't been published). If you want your personal details removed from your submission, please let us know below. We will take this into account when responding to requests under the Official Information Act.	<ul> <li>Include my personal details in responses to Official Information Act requests</li> <li>Remove my personal details from responses to Official Information Act requests</li> </ul>	
Please let us know any other information that you would like us	Please provide your answer below	
to remove from your response.		
Page 2: General questions		
Please describe your current role (Click all that apply).	<ul> <li>Pharmacist working on a hospital ward</li> <li>Pharmacist working in an inpatient hospital pharmacy</li> <li>Pharmacist working in an outpatient clinic</li> <li>Pharmacist working in a community pharmacy</li> <li>Pharmacist working in general practice</li> <li>Pharmacist working in rest homes</li> <li>Other role: please comment below role and location (including intern pharmacist)</li> </ul>	
Approximately, how long have you been looking after people who take clozapine?	Duration (years)	
Approximately, how many people who are on clozapine do you currently dispense and/or review prescriptions for (including inpatient medicine charts)?	<ul> <li>1 - 10</li> <li>11 - 20</li> <li>21 - 30</li> <li>&gt; 31</li> <li>Not applicable or other: please provide further information below</li> </ul>	
Of these people, approximately what proportion have been treated with clozapine for over 1 year on a continuous basis.	<ul> <li>0 - 10%</li> <li>11 - 20%</li> <li>21 - 50%</li> <li>&gt; 51%</li> <li>Not applicable</li> </ul>	
Which resources do you use for information about clozapine in your everyday role? (Click all that apply)	<ul> <li>Data sheet</li> <li>Hospital protocols or guidelines</li> <li>National protocols or guidelines</li> <li>International protocols or guidelines</li> <li>Peer-reviewed journal articles</li> <li>Hospital medicine information services</li> </ul>	



<b>Page 3: Clozapine side effects</b> In general, how often do you ask patients if they are experiencing any potential side effects of clozapine? (you may select more than one option)	<ul> <li>Ask colleagues (pharmacist/pharmacy team)</li> <li>Ask colleagues (other healthcare professionals)</li> <li>Clozapine patient education resources (e.g., Consumer Medicines Information leaflet, Healthify (formerly Health Navigator))</li> <li>Clozapine Patient Monitoring Services provided by pharmaceutical company</li> <li>Other resources: please provide further information below</li> </ul> • Weekly <ul> <li>4-weekly</li> <li>12-weekly</li> <li>Ward rounds/ward visits</li> <li>When medicines are collected from the pharmacy</li> <li>Not applicable or other: please provide further information below.</li> </ul>
Which clozapine side effects do you usually ask about? (Click all that apply)	<ul> <li>Constipation</li> <li>Symptoms of infection</li> <li>Cardiovascular conditions</li> <li>Sedation</li> <li>Hypersalivation</li> <li>Other side effects: please provide further information below</li> </ul>
In general, how are potential clozapine side effects identified? (Click all that apply)	<ul> <li>Patients proactively inform you</li> <li>Asking patients directly</li> <li>Routine monitoring</li> <li>Not applicable or other</li> <li>If you would like to provide further information, please provide your answer below</li> </ul>
If your patients have an adverse reaction to clozapine, do you report it to the Centre for Adverse Reactions Monitoring (CARM) New Zealand?	<ul> <li>Yes</li> <li>No</li> <li>Not applicable or other</li> <li>If you would like to provide any additional information, please provide this below</li> </ul>
Page 4: Constipation	
Approximately, what proportion of your current patients experience constipation with clozapine?	<ul> <li>0 - 10%</li> <li>11 - 20%</li> <li>21 - 50%</li> <li>&gt; 51%</li> <li>Not applicable or other: please provide further information below</li> </ul>
Do you routinely recommend (or prescribe) laxatives for patients taking clozapine?	<ul> <li>Yes: regular laxative to be taken at least daily</li> <li>Yes: laxative to be taken if required</li> <li>No: please provide further information below</li> <li>Not applicable or other: please provide further information below</li> <li>Please provide your answer below</li> </ul>
Do you have anything you would like to tell us about clozapine associated constipation? (e.g., patients needing hospital treatment or had to stop clozapine due to bowel problems, challenges with monitoring or treating constipation)	Please provide your answer below
Page 5: Haematological monitoring	
Please tell us more about your role in haematological monitoring of clozapine (if applicable).	Please provide your answer below
Approximately, what proportion of your current clozapine patients are on weekly, fortnightly, or 4-weekly haematological monitoring?	Weekly (%) _ Fortnightly (%) _ Every 4 weeks (%) _ Not applicable or other: please comment



Approximately, what proportion of your current patients have had to interrupt or discontinue clozapine due to an abnormal blood test result?	<ul> <li>0 - 10%</li> <li>11 - 20%</li> <li>21 - 50%</li> <li>&gt;51%</li> <li>Not applicable or other: please provide further information below</li> </ul>
In patients who have experienced agranulocytosis with clozapine, how was this mostly identified?	<ul> <li>Routine blood test</li> <li>Signs or symptoms that may be indicative of neutropenia resulting in additional blood test</li> <li>Not applicable or other: please provide further information below</li> </ul>
Is there anything you would like to tell us about the benefits or challenges around the mandatory haematological testing?	Please provide your answer below
How could the current haematological testing requirements for clozapine be improved?	Please provide your answer below
Page 6: Feedback	
Do you have any other feedback or information about clozapine that you would like to tell us?	Please provide your answer below.

Medsafe, August 2023